Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Insulins | Research article

The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major

Authors: Soheila Setoodeh, Marjan Khorsand, Mohammad Ali Takhshid

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Background

Serum lipids and glycemic dysregulation are the known characteristics of β- thalassemia major (β-TM). Here, we evaluated the association of these disorders with insulin resistance (IR), oxidative stress and serum ferritin values in patients with β-TM.

Methods

This case-control study was performed in thalassemia unite of Darab Hospital (Darab, Fars province, Iran) from December 2016 to December 2017. Forty-eight patients with β-TM and 33 healthy individuals were enrolled. Serum fasting blood sugar (FBS), insulin, total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), ischemia modified albumin (IMA), and ferritin were measured. The values of HOMA-IR, LDL: TG ratio, atherogenic index (AI), atherogenic index of plasma (AIP), and coronary risk index (CRI) were calculated.

Results

The level of serum ferritin, IMA, FBS, TG, AIP, LDL: TG ratio, and the prevalence of IR (HOMA-IR < 3.8) were significantly higher while TC, LDL-C, HDL-C, and AI were significantly lower in the patients compared to the control group. In patient with β-TM, serum ferritin revealed to have a positive association with serum insulin, HOMA-IR, AI, and CRI levels while serum IMA showed positive association with TG and AIP and inverse association with hypocholesterolemia. HOMA-IR had positive correlation with HDL levels.

Conclusions

Oxidative stress and iron overload are predictors of serum glycemic and lipid dysregulation, suggesting possible beneficial effect of antioxidants and efficient iron chelating therapy in reducing the risk of metabolic disorders in β- thalassemia.
Literature
1.
go back to reference Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood reviews. 2012;26:16-S9.CrossRef Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood reviews. 2012;26:16-S9.CrossRef
2.
go back to reference Koohi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis. Annals of hematology. 2019;98(6):1323–31.CrossRef Koohi F, Kazemi T, Miri-Moghaddam E. Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis. Annals of hematology. 2019;98(6):1323–31.CrossRef
3.
go back to reference Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert review of hematology. 2020;13(1):85–94.CrossRef Motta I, Mancarella M, Marcon A, Vicenzi M, Cappellini MD. Management of age-associated medical complications in patients with β-thalassemia. Expert review of hematology. 2020;13(1):85–94.CrossRef
4.
go back to reference Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2012;87(2):155–60CrossRef Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol. 2012;87(2):155–60CrossRef
5.
go back to reference Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016;10(3):472–89.CrossRef Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016;10(3):472–89.CrossRef
6.
go back to reference Boudrahem-Addour N, Izem-Meziane M, Bouguerra K, Nadjem N, Zidani N, Belhani M, et al. Oxidative status and plasma lipid profile in β-thalassemia patients. Hemoglobin. 2015;39(1):36–41.CrossRef Boudrahem-Addour N, Izem-Meziane M, Bouguerra K, Nadjem N, Zidani N, Belhani M, et al. Oxidative status and plasma lipid profile in β-thalassemia patients. Hemoglobin. 2015;39(1):36–41.CrossRef
7.
go back to reference Ragab SM, Safan MA, Obeid OM, Sherief AS. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children. Hematology. 2015;20(4):228–38.CrossRef Ragab SM, Safan MA, Obeid OM, Sherief AS. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children. Hematology. 2015;20(4):228–38.CrossRef
8.
go back to reference Sherief LM, Dawood O, Ali A, Sherbiny HS, Kamal NM, Elshanshory M, et al. Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker. BMC Pediatr. 2017;17(1):69.CrossRef Sherief LM, Dawood O, Ali A, Sherbiny HS, Kamal NM, Elshanshory M, et al. Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker. BMC Pediatr. 2017;17(1):69.CrossRef
9.
go back to reference Luo Y, Bajoria R, Lai Y, Pan H, Li Q, Zhang Z, et al. Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia. Diabetes metabolic syndrome obesity: targets therapy. 2019;12:457.CrossRef Luo Y, Bajoria R, Lai Y, Pan H, Li Q, Zhang Z, et al. Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia. Diabetes metabolic syndrome obesity: targets therapy. 2019;12:457.CrossRef
10.
go back to reference Hezaveh ZS, Azarkeivan A, Janani L, Shidfar F. Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial. J Res Med Sci. 2019;24. Hezaveh ZS, Azarkeivan A, Janani L, Shidfar F. Effect of quercetin on oxidative stress and liver function in beta-thalassemia major patients receiving desferrioxamine: A double-blind randomized clinical trial. J Res Med Sci. 2019;24.
11.
go back to reference Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A et al. Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with beta-thalassemia. J Lipid Res. 2010;51(11):3331–41CrossRef Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A et al. Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with beta-thalassemia. J Lipid Res. 2010;51(11):3331–41CrossRef
12.
go back to reference Al IO, Ayçiçek A, Ersoy G, Bayram C, Neselioglu S, Erel Ö. Thiol Disulfide Homeostasis and Ischemia-modified Albumin Level in Children With Beta-Thalassemia. J Pediatr Hematol Oncol. 2019;41(7):e463-e6. Al IO, Ayçiçek A, Ersoy G, Bayram C, Neselioglu S, Erel Ö. Thiol Disulfide Homeostasis and Ischemia-modified Albumin Level in Children With Beta-Thalassemia. J Pediatr Hematol Oncol. 2019;41(7):e463-e6.
13.
go back to reference Awadallah SM, Atoum MF, Nimer NA, Saleh SA. Ischemia modified albumin: An oxidative stress marker in β-thalassemia major. Clin Chim Acta. 2012;413(9–10):907–10.CrossRef Awadallah SM, Atoum MF, Nimer NA, Saleh SA. Ischemia modified albumin: An oxidative stress marker in β-thalassemia major. Clin Chim Acta. 2012;413(9–10):907–10.CrossRef
14.
go back to reference Adly AAM, ElSherif NHK, Ismail EAR, Ibrahim YA, Niazi G, Elmetwally SH. Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major. Redox Rep. 2017;22(6):430–8.CrossRef Adly AAM, ElSherif NHK, Ismail EAR, Ibrahim YA, Niazi G, Elmetwally SH. Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major. Redox Rep. 2017;22(6):430–8.CrossRef
15.
go back to reference Elbeblawy N, Abdelmaksoud A, Elguindy W, Elshinawy D, Abdelwahed G. Ischemia modified albumin in Egyptian patients with β-thalassemia major: relation to cardiac complications. QJM. 2018;111(suppl_1):hcy200 Elbeblawy N, Abdelmaksoud A, Elguindy W, Elshinawy D, Abdelwahed G. Ischemia modified albumin in Egyptian patients with β-thalassemia major: relation to cardiac complications. QJM. 2018;111(suppl_1):hcy200
16.
go back to reference Ordovas JM. Gene-diet interactions and cardiovascular diseases: Saturated and monounsaturated fat. Principles of nutrigenetics and nutrigenomics: Elsevier, Amsterdam; 2020. p. 211 – 22. Ordovas JM. Gene-diet interactions and cardiovascular diseases: Saturated and monounsaturated fat. Principles of nutrigenetics and nutrigenomics: Elsevier, Amsterdam; 2020. p. 211 – 22.
17.
go back to reference Buckner JD, Zvolensky MJ, Businelle MS, Gallagher MW. Direct and indirect effects of false safety behaviors on cannabis use and related problems. Am J Addict. 2018;27(1):29–34CrossRef Buckner JD, Zvolensky MJ, Businelle MS, Gallagher MW. Direct and indirect effects of false safety behaviors on cannabis use and related problems. Am J Addict. 2018;27(1):29–34CrossRef
18.
go back to reference Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114(14):2861–8CrossRef Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114(14):2861–8CrossRef
19.
go back to reference Asadi P, Vessal M, Khorsand M, Takhshid MA. Erythrocyte glucose-6-phosphate dehydrogenase activity and risk of gestational diabetes. J Diabetes Metab Disord. 2019;18(2):533–41CrossRef Asadi P, Vessal M, Khorsand M, Takhshid MA. Erythrocyte glucose-6-phosphate dehydrogenase activity and risk of gestational diabetes. J Diabetes Metab Disord. 2019;18(2):533–41CrossRef
20.
go back to reference Keshavarzi F, Rastegar M, Vessal M, Dehbidi GR, Khorsand M, Ganjkarimi AH et al. Serum ischemia modified albumin is a possible new marker of oxidative stress in phenylketonuria. Metab Brain Dis. 2018;33(3):675–80CrossRef Keshavarzi F, Rastegar M, Vessal M, Dehbidi GR, Khorsand M, Ganjkarimi AH et al. Serum ischemia modified albumin is a possible new marker of oxidative stress in phenylketonuria. Metab Brain Dis. 2018;33(3):675–80CrossRef
21.
go back to reference Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology 2014, the American Society of Hematology. Education Program Book. 2017;2017(1):265–71PubMed Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology 2014, the American Society of Hematology. Education Program Book. 2017;2017(1):265–71PubMed
22.
go back to reference Coverdale JP, Katundu KG, Sobczak AI, Arya S, Blindauer CA, Stewart AJ. Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding. Prostaglandins Leukot Essent Fatty Acids. 2018;135:147–57.CrossRef Coverdale JP, Katundu KG, Sobczak AI, Arya S, Blindauer CA, Stewart AJ. Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding. Prostaglandins Leukot Essent Fatty Acids. 2018;135:147–57.CrossRef
23.
go back to reference Takhshid M, Kojuri J, Tabei S, Tavasouli A, Heidary S, Tabandeh M. Early diagnosis of acute coronary syndrome with sensitive troponin I and ischemia modified albumin. 2010. Takhshid M, Kojuri J, Tabei S, Tavasouli A, Heidary S, Tabandeh M. Early diagnosis of acute coronary syndrome with sensitive troponin I and ischemia modified albumin. 2010.
24.
go back to reference El-Farrash RA, Ismail EA, Nada AS, Hassan KY. Ischemia modified albumin levels in infants of diabetic mother: Relation to maternal glycemic control. Egypt J Pediatr. 2017;394(5961):1–6 El-Farrash RA, Ismail EA, Nada AS, Hassan KY. Ischemia modified albumin levels in infants of diabetic mother: Relation to maternal glycemic control. Egypt J Pediatr. 2017;394(5961):1–6
25.
go back to reference Ghergherehchi R, Habibzadeh A. Insulin resistance and β cell function in patients with β-thalassemia major. Hemoglobin. 2015;39(1):69–73.CrossRef Ghergherehchi R, Habibzadeh A. Insulin resistance and β cell function in patients with β-thalassemia major. Hemoglobin. 2015;39(1):69–73.CrossRef
26.
go back to reference Soliman A, Yassin M, Al Yafei F, Al-Naimi L, Almarri N, Sabt A et al. Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX) therapy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014025. Soliman A, Yassin M, Al Yafei F, Al-Naimi L, Almarri N, Sabt A et al. Longitudinal study on liver functions in patients with thalassemia major before and after deferasirox (DFX) therapy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014025.
27.
go back to reference Amin A, Jalali S, Amin R, Aale-yasin S, Jamalian N, Karimi M. Evaluation of the serum levels of immunoglobulin and complement factors in b-thalassemia major patients in Southern Iran. Iran J Immunol. 2005;2(4):220–5 Amin A, Jalali S, Amin R, Aale-yasin S, Jamalian N, Karimi M. Evaluation of the serum levels of immunoglobulin and complement factors in b-thalassemia major patients in Southern Iran. Iran J Immunol. 2005;2(4):220–5
28.
go back to reference Shanab A, El-Desouky M, Kholoussi N, El-Kamah G, Fahmi A. Evaluation of neopterin as a prognostic factor in patients with beta-thalassemia, in comparison with cytokines and immunoglobulins. Arch Hell Med/Arheia Ellenikes Iatrikes. 2015;32(1). Shanab A, El-Desouky M, Kholoussi N, El-Kamah G, Fahmi A. Evaluation of neopterin as a prognostic factor in patients with beta-thalassemia, in comparison with cytokines and immunoglobulins. Arch Hell Med/Arheia Ellenikes Iatrikes. 2015;32(1).
29.
go back to reference Ayyash H, Sirdah M. Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study. Int J Health Sci. 2018;12(6):18 Ayyash H, Sirdah M. Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study. Int J Health Sci. 2018;12(6):18
30.
go back to reference Balci YI, Ünal S, Gümrük F. Serum lipids in Turkish patients with [Beta]-Thalassemia Major and [Beta]-Thalassemia Minor/Türk [Beta]-Talasemi Majör ve [Beta]-Talasemi Minör Hastalarinin serum lipidleri. Turk J Haematol. 2016;33(1):42 Balci YI, Ünal S, Gümrük F. Serum lipids in Turkish patients with [Beta]-Thalassemia Major and [Beta]-Thalassemia Minor/Türk [Beta]-Talasemi Majör ve [Beta]-Talasemi Minör Hastalarinin serum lipidleri. Turk J Haematol. 2016;33(1):42
31.
go back to reference Ibrahim HA, Zakaria SS, Elbatch MM, Ramadan M. New insight on premature atherosclerosis in Egyptian children with β-thalassemia major. 2018. Ibrahim HA, Zakaria SS, Elbatch MM, Ramadan M. New insight on premature atherosclerosis in Egyptian children with β-thalassemia major. 2018.
32.
go back to reference Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A et al. Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β-thalassemia. J Lipid Res. 2010;51(11):3331–41CrossRef Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A et al. Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β-thalassemia. J Lipid Res. 2010;51(11):3331–41CrossRef
33.
go back to reference Arıca V, Arıca S, Özer C, Çevik M. Serum lipid values in children with beta thalassemia major. Pediatr Ther. 2012;2(5):1–3CrossRef Arıca V, Arıca S, Özer C, Çevik M. Serum lipid values in children with beta thalassemia major. Pediatr Ther. 2012;2(5):1–3CrossRef
34.
go back to reference Haghpanah S, Davani M, Samadi B, Ashrafi A, Karimi M. Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. J Res Med Sci. 2010;15(3):150PubMedPubMedCentral Haghpanah S, Davani M, Samadi B, Ashrafi A, Karimi M. Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran. J Res Med Sci. 2010;15(3):150PubMedPubMedCentral
35.
go back to reference Kim YE, Kim DH, Roh YK, Ju SY, Yoon YJ, Nam GE et al. Relationship between Serum Ferritin Levels and Dyslipidemia in Korean Adolescents. PLoS One. 2016;11(4):e0153167CrossRef Kim YE, Kim DH, Roh YK, Ju SY, Yoon YJ, Nam GE et al. Relationship between Serum Ferritin Levels and Dyslipidemia in Korean Adolescents. PLoS One. 2016;11(4):e0153167CrossRef
36.
go back to reference Calandra S, Bertolini S, Pes GM, Deiana L, Tarugi P, Pisciotta L et al, editors Β-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Seminars in vascular medicine; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New &#8230. Calandra S, Bertolini S, Pes GM, Deiana L, Tarugi P, Pisciotta L et al, editors Β-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Seminars in vascular medicine; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New &#8230.
37.
go back to reference Tangvarasittichai S, Pimanprom A, Choowet A, Tangvarasittichai O. Association of iron overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia major and beta-thalassemia/HbE patients. Clin Lab. 2013;59(7–8):861–8.PubMed Tangvarasittichai S, Pimanprom A, Choowet A, Tangvarasittichai O. Association of iron overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia major and beta-thalassemia/HbE patients. Clin Lab. 2013;59(7–8):861–8.PubMed
38.
go back to reference Sonuga OO, Abbiyesuku FM, Adedapo KS, Sonuga AA. Insulin resistance index and proatherogenic lipid indices in the offspring of people with diabetes. Int J Diabetes Metab. 2019;25(1–2):11–8CrossRef Sonuga OO, Abbiyesuku FM, Adedapo KS, Sonuga AA. Insulin resistance index and proatherogenic lipid indices in the offspring of people with diabetes. Int J Diabetes Metab. 2019;25(1–2):11–8CrossRef
39.
go back to reference El-Samahy MH, Tantawy AA, Adly AA, Abdelmaksoud AA, Ismail EA, Salah NY. Evaluation of continuous glucose monitoring system for detection of alterations in glucose homeostasis in pediatric patients with β‐thalassemia major. Pediatr Diabetes. 2019;20(1):65–72.CrossRef El-Samahy MH, Tantawy AA, Adly AA, Abdelmaksoud AA, Ismail EA, Salah NY. Evaluation of continuous glucose monitoring system for detection of alterations in glucose homeostasis in pediatric patients with β‐thalassemia major. Pediatr Diabetes. 2019;20(1):65–72.CrossRef
Metadata
Title
The effects of iron overload, insulin resistance and oxidative stress on metabolic disorders in patients with β- thalassemia major
Authors
Soheila Setoodeh
Marjan Khorsand
Mohammad Ali Takhshid
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00560-x

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.